|
|
|
|
Cutting-edge nanotechnology is now emerging, able to address bioavailability challenges and deliver higher drug loads in more patient-friendly formats with fewer and smaller pills and easier regimens.
|
|
|
|
|
Review the pros and cons of marketed amorphous solid dispersions with so-far unpublished data as well as a green alternative to ASDs: best-in-class nanotechnology to manufacture nanocrystals.
|
|
|
|
|
Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.
|
|
|
|
|
Christian Jones, Chief Commercial Officer, shares the latest in nanotechnology advancements including recent clinical data, formulation applications, and API optimization to NanoImprove formulations.
|
|
|
|
|
|
|
